

Joshua B Rubin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5934419/publications.pdf>

Version: 2024-02-01

121
papers

5,763
citations

168829

31
h-index

97045

71
g-index

132
all docs

132
docs citations

132
times ranked

9808
citing authors

#	ARTICLE	IF	CITATIONS
1	Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas. <i>Neuro-Oncology</i> , 2022, 24, 302-310.	0.6	29
2	A review of bioeffects induced by focused ultrasound combined with microbubbles on the neurovascular unit. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, 42, 3-26.	2.4	13
3	A randomized feasibility study evaluating temozolomide circadian medicine in patients with glioma. <i>Neuro-Oncology Practice</i> , 2022, 9, 193-200.	1.0	11
4	Genetic and histopathological associations with outcome in pediatric pilocytic astrocytoma. <i>Journal of Neurosurgery: Pediatrics</i> , 2022, 29, 504-512.	0.8	3
5	The spectrum of sex differences in cancer. <i>Trends in Cancer</i> , 2022, 8, 303-315.	3.8	38
6	⁶⁴ Cu-Targeted Imaging in Glioblastoma Multiforme Using ⁶⁴ Cu-Radiolabeled Ultrasmall Gold Nanoclusters. <i>ACS Applied Bio Materials</i> , 2022, 5, 235-242.	2.3	3
7	RONC-12. Evaluation of brain network segregation using resting state functional MRI in pediatric brain tumor patients treated with proton beam therapy. <i>Neuro-Oncology</i> , 2022, 24, i179-i179.	0.6	0
8	OTHR-17. Guidance for providing families with autopsy research results. <i>Neuro-Oncology</i> , 2022, 24, i150-i150.	0.6	0
9	LGG-52. Volumetry-based response characterization of recurrent pediatric low-grade gliomas in PNO clinical Neuro-oncology trials. <i>Neuro-Oncology</i> , 2022, 24, i100-i100.	0.6	0
10	GCT-06. Management of a congenital intracranial teratoma: a case report and review of literature. <i>Neuro-Oncology</i> , 2022, 24, i55-i55.	0.6	0
11	EPCT-07. Updated report on the pilot study of using MRI-guided laser heat ablation to induce disruption of the peritumoral blood brain barrier to enhance deliver and efficacy of treatment of pediatric brain tumors. <i>Neuro-Oncology</i> , 2022, 24, i37-i37.	0.6	1
12	Sex differences in health and disease: A review of biological sex differences relevant to cancer with a spotlight on glioma. <i>Cancer Letters</i> , 2021, 498, 178-187.	3.2	30
13	Temozolomide chronotherapy in patients with glioblastoma: a retrospective single-institute study. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab041.	0.4	28
14	Diffusion histology imaging differentiates distinct pediatric brain tumor histology. <i>Scientific Reports</i> , 2021, 11, 4749.	1.6	9
15	Focused Ultrasound-Enhanced Delivery of Intranasally Administered Anti-Programmed Cell Death-Ligand 1 Antibody to an Intracranial Murine Glioma Model. <i>Pharmaceutics</i> , 2021, 13, 190.	2.0	24
16	The transcriptional landscape of Shh medulloblastoma. <i>Nature Communications</i> , 2021, 12, 1749.	5.8	47
17	Sex disparities matter in cancer development and therapy. <i>Nature Reviews Cancer</i> , 2021, 21, 393-407.	12.8	136
18	Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	28

#	ARTICLE	IF	CITATIONS
19	HGG-17. FOCUSED ULTRASOUND-ENHANCED DELIVERY OF RADIOLABELED AGENTS TO DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2021, 23, i20-i21.	0.6	0
20	OMIC-13. THE ROLE OF COPY NUMBER ALTERATIONS IN PREDICTING SURVIVAL AND INFLUENCING TREATMENT OF CHILDHOOD BRAIN TUMORS. <i>Neuro-Oncology</i> , 2021, 23, i40-i40.	0.6	0
21	OMIC-10. TRANSCRIPTOMIC ANALYSIS REVEALS SEX DIFFERENCES IN PEDIATRIC BRAIN MECHANISMS. <i>Neuro-Oncology</i> , 2021, 23, i39-i39.	0.6	0
22	Molecular omics resources should require sex annotation: a call for action. <i>Nature Methods</i> , 2021, 18, 585-588.	9.0	17
23	Subgroup and subtype-specific outcomes in adult medulloblastoma. <i>Acta Neuropathologica</i> , 2021, 142, 859-871.	3.9	34
24	Sexual Differentiation Specifies Cellular Responses to DNA Damage. <i>Endocrinology</i> , 2021, 162, .	1.4	7
25	BRAF mutations may identify a clinically distinct subset of glioblastoma. <i>Scientific Reports</i> , 2021, 11, 19999.	1.6	15
26	Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. <i>Journal of Neuro-Oncology</i> , 2021, 155, 363-372.	1.4	11
27	Sex- and Mutation-Specific p53 Gain-of-Function Activity in Gliomagenesis. <i>Cancer Research Communications</i> , 2021, 1, 148-163.	0.7	6
28	Editorial: Sex Difference in Cancer Genomics and Its Impact on Therapy. <i>Frontiers in Genetics</i> , 2021, 12, 815804.	1.1	0
29	Altered hemodynamics contribute to local but not remote functional connectivity disruption due to glioma growth. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 100-115.	2.4	20
30	Characterization of focused ultrasound-mediated brainstem delivery of intranasally administered agents. <i>Journal of Controlled Release</i> , 2020, 328, 276-285.	4.8	11
31	Magnetic Resonance Imaging-Guided Focused Ultrasound-Based Delivery of Radiolabeled Copper Nanoclusters to Diffuse Intrinsic Pontine Glioma. <i>ACS Applied Nano Materials</i> , 2020, 3, 11129-11134.	2.4	17
32	Sex and gender: modifiers of health, disease, and medicine. <i>Lancet, The</i> , 2020, 396, 565-582.	6.3	955
33	Sex Differences in Cancer Incidence and Survival: A Pan-Cancer Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1389-1397.	1.1	82
34	Sex-specific impact of patterns of imageable tumor growth on survival of primary glioblastoma patients. <i>BMC Cancer</i> , 2020, 20, 447.	1.1	20
35	Gliomas display distinct sex-based differential methylation patterns based on molecular subtype. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa002.	0.4	15
36	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. <i>Cell Reports Medicine</i> , 2020, 1, 100038.	3.3	24

#	ARTICLE	IF	CITATIONS
37	JAM-A functions as a female microglial tumor suppressor in glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 1591-1601.	0.6	26
38	Sexually dimorphic impact of the iron-regulating gene, HFE, on survival in glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa001.	0.4	2
39	Sex differences in cancer mechanisms. <i>Biology of Sex Differences</i> , 2020, 11, 17.	1.8	169
40	Effect of temozolomide chronotherapy in patients with high-grade glioma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e14525-e14525.	0.8	2
41	TBIO-01. SEX DIFFERENCES IN REDOX STATE UNDERLIE GLUTAMINE DEPENDENCY IN MALE GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, iii467-iii467.	0.6	0
42	TAMI-34. SEX-SPECIFIC METABOLIC ADAPTATIONS TO THE KETOGENIC DIET IN A MOUSE MODEL OF GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii220-ii220.	0.6	0
43	TAMI-43. IMPACT OF SEX AND RADIATION ON IRON TRAFFICKING IN BONE MARROW DERIVED MACROPHAGES. <i>Neuro-Oncology</i> , 2020, 22, ii222-ii222.	0.6	0
44	TAMI-37. SEX DIFFERENCES IN REDOX STATE UNDERLIE GLUTAMINE DEPENDENCY IN MALE GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii221-ii221.	0.6	0
45	CBIO-22. p53 GAIN-OF-FUNCTION MUTATIONS DRIVE SEX SPECIFIC EFFECTS ON GLIOMA TUMORIGENESIS. <i>Neuro-Oncology</i> , 2020, 22, ii20-ii20.	0.6	0
46	CSIG-16. SEXUAL DIMPORHISM IN IRON ACQUISITION IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii31-ii31.	0.6	1
47	CBIO-08. ASTROCYTE SENESENCE CONTRIBUTES TO SEX DIFFERENCES IN GLIOBLASTOMA INCIDENCE AND OUTCOME. <i>Neuro-Oncology</i> , 2020, 22, ii17-ii17.	0.6	1
48	NCOG-69. SEX DIFFERENCES IN GLIOBLASTOMA PATIENT SURVIVAL AS A FUNCTION OF EXTENT OF SURGICAL RESECTION AND CYCLES OF ADJUVANT TEMOZOLOMIDE DURING STANDARD-OF-CARE REGIMENS. <i>Neuro-Oncology</i> , 2020, 22, ii144-ii145.	0.6	0
49	TAMI-17. RELATIONSHIP BETWEEN IRON METABOLISM, IMMUNE CELL INFILTRATION AND SEX-BASED SURVIVAL DIFFERENCES IN GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, ii216-ii216.	0.6	0
50	Sex-specific gene and pathway modeling of inherited glioma risk. <i>Neuro-Oncology</i> , 2019, 21, 71-82.	0.6	52
51	To each, his/her own. <i>Neuro-Oncology</i> , 2019, 21, 1217-1218.	0.6	1
52	Sex is an important prognostic factor for glioblastoma but not for nonglioblastoma. <i>Neuro-Oncology Practice</i> , 2019, 6, 451-462.	1.0	36
53	GENE-10. DEVELOPMENTAL ORIGINS OF SEX DIFFERENCES IN RESPONSE TO TUMOR SUPPRESSOR LOSS. <i>Neuro-Oncology</i> , 2019, 21, ii83-ii83.	0.6	0
54	CBMT-45. SEX-SPECIFIC METABOLIC ADAPTIONS IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, vi42-vi43.	0.6	0

#	ARTICLE	IF	CITATIONS
55	TMIC-02. JUNCTIONAL ADHESION MOLECULE-A (JAM-A) DEFICIENCY DRIVES SEX-SPECIFIC DIFFERENCES IN GLIOBLASTOMA PROGRESSION VIA DIFFERENTIAL MICROGLIA RESPONSES IN THE TUMOR MICROENVIRONMENT. <i>Neuro-Oncology</i> , 2019, 21, vi247-vi247.	0.6	0
56	TMIC-17. ASTROCYTE SENESENCE CONTRIBUTES TO SEX DIFFERENCES IN THE AGE-RELATED INCREASE IN GLIOBLASTOMA INCIDENCE. <i>Neuro-Oncology</i> , 2019, 21, vi250-vi251.	0.6	0
57	NIMG-64. IMPACT OF TUMOR LOCATION ON IMAGE-DERIVED VOLUME, PROLIFERATION RATE AND GROWTH VELOCITY IN GLIOBLASTOMA PATIENTS. <i>Neuro-Oncology</i> , 2019, 21, vi175-vi176.	0.6	0
58	NIMG-58. SEX DIFFERENCES IN CONTRAST-ENHANCING GLIOMAS AT PRESENTATION. <i>Neuro-Oncology</i> , 2019, 21, vi174-vi174.	0.6	1
59	EPID-01. SEX DIFFERENCE IN EXPRESSION OF IRON-RELATED GENES AND SURVIVAL IN GLIOBLASTOMA PATIENTS. <i>Neuro-Oncology</i> , 2019, 21, vi74-vi74.	0.6	0
60	NIMG-37. PREDICTING SEIZURE IN GLIOMA PATIENTS USING A RANDOM FOREST CLASSIFIER TRAINED ON SEX-SPECIFIC AND MIXED COHORTS. <i>Neuro-Oncology</i> , 2019, 21, vi169-vi169.	0.6	0
61	TMIC-53. IMPACT OF HFE EXPRESSION AND SEX ON THE TUMOR IMMUNE MICROENVIRONMENT IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, vi259-vi259.	0.6	0
62	EPID-03. HISTOLOGY-SPECIFIC BRAIN TUMOR INCIDENCE AND SURVIVAL VARIES BY SEX. <i>Neuro-Oncology</i> , 2019, 21, vi74-vi75.	0.6	0
63	TMIC-31. IMPACT OF IRON ON MACROPHAGE IMMUNE PHENOTYPE IN THE GLIOBLASTOMA TUMOR MICROENVIRONMENT. <i>Neuro-Oncology</i> , 2019, 21, vi254-vi254.	0.6	0
64	TMIC-34. SENESENCE INDUCED INFLAMMATION MAY UNDERLIE SEX DIFFERENCES IN THE AGE-DEPENDENT RISE IN GLIOBLASTOMA INCIDENCE. <i>Neuro-Oncology</i> , 2019, 21, vi255-vi255.	0.6	0
65	GENE-59. NOT ALL p53 MUTATIONS ARE CREATED EQUAL: A MURINE ASTROCYTE MODEL FOR HIGH-THROUGHPUT FUNCTIONAL ASSESSMENT OF p53 MISSENSE MUTATIONS. <i>Neuro-Oncology</i> , 2019, 21, vi110-vi110.	0.6	0
66	Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma. <i>Nature</i> , 2019, 574, 707-711.	13.7	129
67	Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	230
68	Females have the survival advantage in glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 576-577.	0.6	122
69	Resistance-promoting effects of ependymoma treatment revealed through genomic analysis of multiple recurrences in a single patient. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002444.	0.5	16
70	Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. <i>Cancer Cell</i> , 2018, 33, 292-308.e7.	7.7	83
71	A histone deacetylase 3-dependent pathway delimits peripheral myelin growth and functional regeneration. <i>Nature Medicine</i> , 2018, 24, 338-351.	15.2	76
72	Fetal microchimerism in human brain tumors. <i>Brain Pathology</i> , 2018, 28, 484-494.	2.1	19

#	ARTICLE	IF	CITATIONS
73	CBMT-22. The PI3K/mTOR PATHWAY CONTRIBUTES TO SEX DIFFERENCES IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi37-vi37.	0.6	0
74	PATH-12. CHARACTERISTICS OF GIANT CELL MORPHOLOGY IN LONG-TERM SURVIVORS OF GLIOBLASTOMA: CONSIDERATION OF SEX DIFFERENCES. <i>Neuro-Oncology</i> , 2018, 20, vi160-vi160.	0.6	2
75	NIMG-12. RADIOGENOMICS ON VENUS AND MARS: IMPACT OF SEX-DIFFERENCES ON MRI AND GENETIC CORRELATIONS IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi178-vi178.	0.6	0
76	TMOD-22. MODELING SEX DIFFERENCES IN p53 GAIN-OF-FUNCTION MUTATIONS IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi273-vi273.	0.6	0
77	NIMG-19. SEX-SPECIFIC BRAIN MAPS FOR RISK OF SEIZURE AMONG GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, vi179-vi180.	0.6	0
78	COMP-09. HFE EXPRESSION ALTERS OUTCOMES IN BRAIN TUMORS. <i>Neuro-Oncology</i> , 2018, 20, vi65-vi65.	0.6	0
79	GENE-19. GAINING A BETTER UNDERSTANDING OF DNA METHYLATION FEATURES ASSOCIATED WITH SEX DIFFERENCES IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi107-vi107.	0.6	1
80	GENE-15. CELL AUTONOMOUS MECHANISMS OF SEX DIFFERENCES IN RESPONSE TO TUMOR SUPPRESSOR LOSS. <i>Neuro-Oncology</i> , 2018, 20, vi105-vi106.	0.6	0
81	TMIC-44. ASTROCYTE SENESCENCE: A MODEL FOR AGE AND SEX EFFECTS ON GLIOBLASTOMA INCIDENCE. <i>Neuro-Oncology</i> , 2018, 20, vi266-vi266.	0.6	0
82	NIMG-07. DEEP LEARNING DETECTS DIFFERENCES IN THE MRIs OF MALE AND FEMALE GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi177-vi177.	0.6	0
83	NIMG-21. SEX DIFFERENCES IN EXTREME SURVIVORSHIP AMONG PRIMARY GLIOBLASTOMA PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, vi180-vi180.	0.6	3
84	NIMG-16. IMPACT OF SEX DIFFERENCES AND TUMOR LOCATION ON SURVIVAL OUTCOMES IN GLIOBLASTOMA PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, vi179-vi179.	0.6	0
85	Age-specific genome-wide association study in glioblastoma identifies increased proportion of "lower grade glioma-like" features associated with younger age. <i>International Journal of Cancer</i> , 2018, 143, 2359-2366.	2.3	21
86	18F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors. <i>Neuro-Oncology Practice</i> , 2018, 5, 28-36.	1.0	17
87	Focused ultrasound-enabled delivery of radiolabeled nanoclusters to the pons. <i>Journal of Controlled Release</i> , 2018, 283, 143-150.	4.8	45
88	Focused Ultrasound Enabled Trans-Cerebral Blood Brain Barrier Delivery of Gold Nanoclusters: Effect of Surface Charges and Quantification Using Positron Emission Tomography. <i>Small</i> , 2018, 14, e1703115.	5.2	29
89	NFM-11. PEDIATRIC MENINGIOMAS ARE MOLECULARLY DISTINCT FROM ADULT COUNTERPARTS. <i>Neuro-Oncology</i> , 2018, 20, i144-i145.	0.6	1
90	Focused ultrasound combined with microbubble-mediated intranasal delivery of gold nanoclusters to the brain. <i>Journal of Controlled Release</i> , 2018, 286, 145-153.	4.8	69

#	ARTICLE	IF	CITATIONS
91	Cooperative p16 and p21 action protects female astrocytes from transformation. <i>Acta Neuropathologica Communications</i> , 2018, 6, 12.	2.4	47
92	Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21. <i>Scientific Reports</i> , 2018, 8, 7352.	1.6	56
93	Randomized feasibility study of temozolomide chronotherapy for high grade glioma.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14035-e14035.	0.8	5
94	Cell-intrinsic, Bmal1-dependent Circadian Regulation of Temozolomide Sensitivity in Glioblastoma. <i>Journal of Biological Rhythms</i> , 2017, 32, 121-129.	1.4	48
95	Intertumoral Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2017, 31, 737-754.e6.	7.7	836
96	Reprogramming Medulloblastoma-Propagating Cells by a Combined Antagonism of Sonic Hedgehog and CXCR4. <i>Cancer Research</i> , 2017, 77, 1416-1426.	0.4	13
97	CBIO-31. SEX DIFFERENCES IN THE ACTIVITY OF CYCLIN DEPENDENT KINASE INHIBITORS UNDERLIE GREATER THRESHOLD FOR GLIOMIC TRANSFORMATION IN FEMALE ASTROCYTES. <i>Neuro-Oncology</i> , 2017, 19, vi38-vi38.	0.6	0
98	Sexual dimorphism in glioma glycolysis underlies sex differences in survival. <i>JCI Insight</i> , 2017, 2, .	2.3	54
99	Geminin deficiency enhances survival in a murine medulloblastoma model by inducing apoptosis of preneoplastic granule neuron precursors. <i>Genes and Cancer</i> , 2017, 8, 725-744.	0.6	1
100	NS-14A PILOT STUDY OF USING MRI-GUIDED LASER HEAT ABLATION TO INDUCE DISRUPTION OF THE PERITUMORAL BLOOD BRAIN BARRIER TO ENHANCE DELIVERY AND EFFICACY OF TREATMENT OF PEDIATRIC BRAIN TUMORS. <i>Neuro-Oncology</i> , 2016, 18, iii129.5-iii130.	0.6	1
101	The Fallacy of Univariate Solutions to Complex Systems Problems. <i>Frontiers in Neuroscience</i> , 2016, 10, 267.	1.4	18
102	Olig2-Dependent Reciprocal Shift in PDGF and EGF Receptor Signaling Regulates Tumor Phenotype and Mitotic Growth in Malignant Glioma. <i>Cancer Cell</i> , 2016, 29, 669-683.	7.7	98
103	Intersections at the crossroads: Neurofibromatosis type 1, cAMP, sex, and glioma risk. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1069917.	0.3	1
104	An integrative view on sex differences in brain tumors. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 3323-3342.	2.4	144
105	CBIO-36p21 REGULATES STEM CELL FREQUENCY IN A SEX-SPECIFIC FASHION. <i>Neuro-Oncology</i> , 2015, 17, v62.3-v62.	0.6	0
106	The Cyclic AMP Pathway Is a Sex-Specific Modifier of Glioma Risk in Type I Neurofibromatosis Patients. <i>Cancer Research</i> , 2015, 75, 16-21.	0.4	56
107	Sexual selection and cancer biology. <i>Oncotarget</i> , 2015, 6, 15714-15715.	0.8	2
108	Novel chemical library screen identifies naturally occurring plant products that specifically disrupt glioblastoma-endothelial cell interactions. <i>Oncotarget</i> , 2015, 6, 18282-18292.	0.8	14

#	ARTICLE	IF	CITATIONS
109	The G protein β subunit $G\beta$ is a tumor suppressor in Sonic hedgehog-driven medulloblastoma. <i>Nature Medicine</i> , 2014, 20, 1035-1042.	15.2	110
110	Sexually dimorphic RB inactivation underlies mesenchymal glioblastoma prevalence in males. <i>Journal of Clinical Investigation</i> , 2014, 124, 4123-4133.	3.9	115
111	PDE7B Is a Novel, Prognostically Significant Mediator of Glioblastoma Growth Whose Expression Is Regulated by Endothelial Cells. <i>PLoS ONE</i> , 2014, 9, e107397.	1.1	22
112	Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma. <i>Oncotarget</i> , 2014, 5, 9811-9822.	0.8	39
113	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 126, 917-929.	3.9	146
114	Antiangiogenic Agents for Nonmalignant Brain Tumors. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2013, 74, 136-141.	0.4	30
115	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. <i>Nature</i> , 2012, 488, 49-56.	13.7	761
116	Why does Jack, and not Jill, break his crown? Sex disparity in brain tumors. <i>Biology of Sex Differences</i> , 2012, 3, 3.	1.8	62
117	Cyclic AMP Suppression Is Sufficient to Induce Gliomagenesis in a Mouse Model of Neurofibromatosis-1. <i>Cancer Research</i> , 2010, 70, 5717-5727.	0.4	102
118	Chemokine signaling in cancer: One hump or two?. <i>Seminars in Cancer Biology</i> , 2009, 19, 116-122.	4.3	69
119	Only in Congenial Soil: The Microenvironment in Brain Tumorigenesis. <i>Brain Pathology</i> , 2009, 19, 144-149.	2.1	8
120	Spatiotemporal Differences in CXCL12 Expression and Cyclic AMP Underlie the Unique Pattern of Optic Glioma Growth in Neurofibromatosis Type 1. <i>Cancer Research</i> , 2007, 67, 8588-8595.	0.4	105
121	Leptomeningeal Disease and Tumor in a Murine DIPG Model: Implications for Study of the Tumor-CSF-Ependymal Microenvironment. <i>Neuro-Oncology Advances</i> , 0, , .	0.4	1